Publications

Breast cancer research and treatment

Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen.

01-07-2014

Breast cancer research and treatment

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms.

01-06-2014

Nederlands tijdschrift voor geneeskunde

[Gene expression classifiers in the prognosis of breast cancer].

02-05-2014

European journal of cancer (Oxford, England : 1990)

Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature.

01-04-2014

The Journal of molecular diagnostics : JMD

MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue.

01-03-2014

Breast cancer research and treatment

Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care.

01-02-2014

BMC cancer

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.

28-12-2013

British journal of cancer

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.

10-12-2013

European journal of cancer (Oxford, England : 1990)

Prospective cost-effectiveness analysis of genomic profiling in breast cancer.

01-12-2013

Cancer research

Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer.

15-11-2013

European journal of pharmacology

Tamoxifen resistance: from bench to bedside.

05-10-2013

Breast (Edinburgh, Scotland)

Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies.

01-10-2013

International journal of cancer

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.

15-08-2013

Breast cancer research and treatment

CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.

01-06-2013

Breast cancer research and treatment

Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.

01-06-2013

The breast journal

Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.

21-05-2013

Breast (Edinburgh, Scotland)

Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.

01-12-2012

Human brain mapping

Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging.

01-12-2012

Nature reviews. Clinical oncology

Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?

01-09-2012

BMC research notes

Scenario drafting to anticipate future developments in technology assessment.

16-08-2012

Journal of cancer research and clinical oncology

Chemotherapy as primary treatment for brain metastases from breast cancer: analysis of 115 one-year survivors.

01-08-2012

Breast cancer research and treatment

Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen.

01-06-2012

Cancer research

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

01-05-2012

Psycho-oncology

Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study.

01-05-2012

Cellular and molecular life sciences : CMLS

Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.

01-01-2012

The EMBO journal

Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer.

14-10-2011

Annals of oncology : official journal of the European Society for Medical Oncology

Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice.

01-09-2011

Annals of oncology : official journal of the European Society for Medical Oncology

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.

01-07-2011

Breast cancer research and treatment

PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer.

01-01-2011

British journal of cancer

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.

07-12-2010

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer.

01-12-2010

Critical reviews in oncology/hematology

Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors.

01-11-2010

Annals of surgical oncology

The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.

01-09-2010

Annals of surgical oncology

Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.

01-05-2010

European journal of cancer (Oxford, England : 1990)

Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.

01-05-2010

Breast cancer research and treatment

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.

01-04-2010

Psycho-oncology

The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy.

01-04-2010

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.

10-03-2010

Annals of oncology : official journal of the European Society for Medical Oncology

A simple system for grading the response of breast cancer to neoadjuvant chemotherapy.

01-03-2010

Annals of oncology : official journal of the European Society for Medical Oncology

The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.

01-01-2010

Journal of the National Cancer Institute

Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer.

16-12-2009

Breast cancer research and treatment

Validation of 70-gene prognosis signature in node-negative breast cancer.

01-10-2009

European journal of cancer (Oxford, England : 1990)

Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept.

01-09-2009

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.

15-08-2009

American journal of surgery

Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy.

01-07-2009

The Journal of pathology

Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.

01-07-2009

Breast cancer research and treatment

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

01-01-2009

International journal of technology assessment in health care

Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics.

01-01-2009

Nederlands tijdschrift voor geneeskunde

[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].

15-11-2008

Acta oncologica (Stockholm, Sweden)

Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.

09-09-2008

Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen.

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms.

[Gene expression classifiers in the prognosis of breast cancer].

Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature.

MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue.

Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care.

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.

Prospective cost-effectiveness analysis of genomic profiling in breast cancer.

Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer.

Tamoxifen resistance: from bench to bedside.

Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies.

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.

CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.

Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.

Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.

Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.

Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging.

Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?

Scenario drafting to anticipate future developments in technology assessment.

Chemotherapy as primary treatment for brain metastases from breast cancer: analysis of 115 one-year survivors.

Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen.

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study.

Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.

Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer.

Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice.

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.

PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer.

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.

Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer.

Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors.

The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.

Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.

Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.

The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy.

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.

A simple system for grading the response of breast cancer to neoadjuvant chemotherapy.

The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.

Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer.

Validation of 70-gene prognosis signature in node-negative breast cancer.

Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept.

Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.

Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy.

Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics.

[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].

Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.

This site uses cookies